pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLC10.18093/0869-0189-2016-26-1-79-84pulmo-676Research ArticleОБЗОРЫREVIEWПрименение комбинации вилантерол / умеклидиния бромид в качестве базисной терапии у пациентов с хронической обструктивной болезнью легкихVilanterol / umeclidinium bromide combination as a basic therapy for chronic obstructive pulmonary diseaseЧикинаС. Ю.ChikinaS. Yu.

к. м. н., старший научный сотрудник лаборатории функциональных и ультразвуковых методов исследования ФГБУ «НИИ пульмонологии» ФМБА; тел.: (495) 967-77-44

PhD, Senior Researcher at Laboratory of Functional and Ultra-sound Investigations; Federal Institution «Pulmonology Research Institute», Federal Medical and Biological Agency of Russia; tel.: (495) 967-77-44;

svch@list.ruФГБУ «НИИ пульмонологии» ФМБА: 105077, Москва, ул. 11-я Парковая, 32, корп. 4РоссияFederal Pulmonology Research Institute, Federal Medical and Biological Agency of Russia: 32, build. 4, 11th Parkovaya str., Moscow, 105077, RussiaRussian Federation2016190420162617984Copyright © Чикина С.Ю., 20162016Чикина С.Ю.Chikina S.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/676

Представлен обзор опубликованных на сегодняшний день данных по клинической эффективности и безопасности новой фиксированной комбинации 2 длительно действующих бронходилататоров с разными механизмами действия в сравнении как с плацебо, так и с монотерапией отдельными ее компонентами и другими ингаляционными длительно действующими бронхолитическими препаратами. Терапия новой фиксированной комбинацией длительно действующего b2-агониста вилантерола (ВИЛ) и длительно действующего М-холинолитика умеклидиния (УМ) бромида у пациентов со среднетяжелой, тяжелой и очень тяжелой хронической обструктивной болезнью легких (ХОБЛ) привела к более выраженному улучшению легочной функции, повышению качества жизни, снижению потребности в сальбутамоле для купирования симптомов и уменьшению одышки на фоне физической нагрузки по сравнению с монотерапией отдельными компонентами и тиотропия бромидом. Препарат хорошо переносился больными. Новый порошковый ингалятор Эллипта, содержащий комбинацию ВИЛ + УМ, оценен большинством больных ХОБЛ как удобный и простой в использовании.

A review of published data on clinical efficacy and safety of a new vilanterol/umeclidinium bromide fixed combination in comparison with its separate components and with other long-acting bronchodilators has been performed in this article. Several randomized controlled large trials demonstrated a higher improvement in the airflow limitation and lung hyperinflation under the treatment with the fixed combination of vilanterol and umeclidinium bromide compared to monotherapy with umeclidinium bromide or vilanterol or tiotropium bromide. Vilanterol/umeclidinium bromide fixed combination also improved exertional dyspnea, quality of life and exercise endurance time in stable patients with moderate to severe or very severe chronic obstructive pulmonary disease (COPD). Good tolerability of the drug was noted in all the studies. Vilanterol/umeclidinium bromide fixed combination is delivered via Ellipta dry powder inhaler which was assessed by most patients as a convenient and easy to use inhaler.

The published data confirmed higher clinical efficacy of dual bronchodilator therapy in patients with COPD of categories B, C and D.

двойная бронходилатационная терапиявилантеролумеклидиния бромидхроническая обструктивная болезнь легкиходышкакачество жизнилегочная функцияdual bronchodilator therapyvilanterolumeclidinium bromidechronic obstructive pulmonary diseasedyspneaquality of lifelung functionReferencesCazzola M., Molimard M. The scientific rationale for combining long acting beta2 agonists and muscarinic antagonists in COPD. Pulm. Pharmacol. Ther. 2010; 23 (4): 257–267.Cazzola M., Molimard M. The scientific rationale for combining long acting beta2 agonists and muscarinic antagonists in COPD. Pulm. Pharmacol. Ther. 2010; 23 (4): 257–267.Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Updated 2015. http://www.goldcopd.org/uploads/users/files/ GOLD_Report_2013_Feb20.pdfGlobal Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Updated 2015. http://www.goldcopd.org/uploads/users/files/ GOLD_Report_2013_Feb20.pdfColeman C.I., Limone B., Sobieraj D.M. et al. Dosing frequency and medication adherence in chronic disease. J. Manag. Care Pharm. 2012; 18 (7): 527–539.Coleman C.I., Limone B., Sobieraj D.M. et al. Dosing frequency and medication adherence in chronic disease. J. Manag. Care Pharm. 2012; 18 (7): 527–539.Decramer M., Anzueto A., Kerwin E. et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir. Med. 2014; 2 (6): 472–486.Decramer M., Anzueto A., Kerwin E. et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir. Med. 2014; 2 (6): 472–486.Celli B., Crater G., Kilbride S. et al. Once daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study. Chest. 2014; 145 (5): 981–991.Celli B., Crater G., Kilbride S. et al. Once daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study. Chest. 2014; 145 (5): 981–991.Donohue J.F., Maleki Yazdi M.R., Kilbride S. et al. Efficacy and safety of once daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir. Med. 2013; 107 (10): 1538–1546.Donohue J.F., Maleki Yazdi M.R., Kilbride S. et al. Efficacy and safety of once daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir. Med. 2013; 107 (10): 1538–1546.Cazzola M., MacNee W., Martinez F.J. et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur. Respir. J. 2008; 31 (2): 416–469.Cazzola M., MacNee W., Martinez F.J. et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur. Respir. J. 2008; 31 (2): 416–469.O'Donnell D.E., Lam M., Webb K.A. Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1998; 158 (5, Pt 1): 1557–1565.O'Donnell D.E., Lam M., Webb K.A. Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1998; 158 (5, Pt 1): 1557–1565.Maltais F., Singh S., Donald A.C. et al. Effects of a combination of umeclidinium/vilanterol on exercise endurance in patients with chronic obstructive pulmonary disease: two randomized, double blind clinical trials. Ther. Adv. Respir. Dis. 2014; 8 (6): 169–181.Maltais F., Singh S., Donald A.C. et al. Effects of a combination of umeclidinium/vilanterol on exercise endurance in patients with chronic obstructive pulmonary disease: two randomized, double blind clinical trials. Ther. Adv. Respir. Dis. 2014; 8 (6): 169–181.Maleki Yazdi M.R., Kaelin T., Richard N. et al. Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24 week, randomized, controlled trial. Respir. Med. 2014; 108 (12): 1752–1760.Maleki Yazdi M.R., Kaelin T., Richard N. et al. Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24 week, randomized, controlled trial. Respir. Med. 2014; 108 (12): 1752–1760.Svedsater H., Jacques L., Goldfrad C., Bleecker E.R. Ease of use of the Ellipta dry powder inhaler: data from three randomized controlled trials in patients with asthma. Primary Care Respir. Med. 2014; 24: 14019. doi: 10.1038/npjpcrm. 2014.19Svedsater H., Jacques L., Goldfrad C., Bleecker E.R. Ease of use of the Ellipta dry powder inhaler: data from three randomized controlled trials in patients with asthma. Primary Care Respir. Med. 2014; 24: 14019. doi: 10.1038/npjpcrm. 2014.19Svedsater H., Dale P., Garrill K. et al. Qualitative assessment of attributes and ease of use of the ELLIPTATM dry powder inhaler for delivery of maintenance therapy for asthma and COPD. BMC Pulm. Med. 2013; 13: 72. doi: 10.1186/1471 2466 13 72.Svedsater H., Dale P., Garrill K. et al. Qualitative assessment of attributes and ease of use of the ELLIPTATM dry powder inhaler for delivery of maintenance therapy for asthma and COPD. BMC Pulm. Med. 2013; 13: 72. doi: 10.1186/1471 2466 13 72.

The authors declare that there are no conflicts of interest present.